Employers
LENZ Therapeutics, the Solana Beach, Calif., company that sells the presbyopia eye drop VIZZ, will shrink its workforce by about three-quarters, leaving approximately 40 full-time employees, according to a Form 8-K filed with the Securities and Exchange Commission on Wednesday, Oct. 28.
The company’s board approved what it calls a strategic reorganization on Oct. 28. In the filing’s Item 2.05, which covers costs associated with exit or disposal activities, LENZ said the plan includes “decreasing the Company’s headcount by approximately 75% to approximately 40 full-time employees.” The company did not state its pre-reorganization headcount or a precise number of positions being eliminated in the filing.
LENZ estimates about $5 million in non-recurring charges, primarily severance payments and related termination benefits. It expects substantially all of those charges to be incurred in the fourth quarter of 2026 and the reorganization to be substantially completed in the same quarter. The company cautioned that the estimate rests on assumptions and that actual costs could differ.
Why the company is cutting
The reorganization comes less than a year into the commercial launch of VIZZ, an aceclidine-based eye drop for presbyopia, the age-related loss of near vision. In its third-quarter earnings release, also dated Oct. 28, LENZ said the plan is meant to “prioritize consumer marketing, allocate capital to maximize sales growth, and reduce operating expenses.”
The company said it expects the changes to cut projected 2027 annualized operating expenses by more than 50%, targeting roughly $70 million to $75 million in 2027 operating expenses, excluding stock-based compensation. LENZ said the smaller structure is intended to keep “the capabilities necessary to support the continued commercialization of VIZZ.”
The spending picture explains the pressure. Selling, general and administrative expenses rose to $35.8 million in the third quarter and $120.2 million for the first nine months of 2026, up from $27.6 million and $51.5 million in the same periods of 2025. The company attributed the increase largely to launch spending, including commercial marketing, advertising, sales infrastructure and personnel-related costs “due to a growth in headcount.”
Against that spending, product sales were $2.6 million in the third quarter on more than 38,000 paid prescriptions, roughly 50% and 51% above the second quarter, respectively. Net loss was $31.0 million for the quarter and $104.4 million for nine months. Cash, cash equivalents and marketable securities stood at $197.3 million as of Sept. 30.
Leadership change
The same filing disclosed a change at the top. President and Chief Executive Eef Schimmelpennink will step down from those roles effective Dec. 1, 2026, and leave the board on that date. Chief Financial Officer Dan Chevallard will become interim president and CEO. Under a separation agreement, Schimmelpennink will remain a full-time employee as strategic advisor to the CEO through Dec. 31, 2026, at his current annual base salary of $731,400. The filing says his departure was not the result of any disagreement with the company.
In the release, Schimmelpennink said he decided to leave “to devote more time to other passions,” and that the company is focusing its commercial organization on initiatives it believes will most effectively increase consumer awareness and adoption.
What it means for workers
The cut is planned, not yet complete: LENZ said it would be carried out during the fourth quarter. The filing does not break the reductions down by function or location, and it does not say which teams are most affected. The release points to a shift toward consumer marketing and telehealth: the company launched a telehealth prescribing option in July 2026 and a nationwide TV advertising campaign the same month, and said telehealth contributed more than 50% of the incremental prescriptions in the third quarter over the second.
The case is a reminder that commercial-stage biotech employment can swing quickly once a launch is underway. A company can hire to support a new product, then cut sharply when it decides a leaner, marketing-led model is cheaper. LENZ said most of the expected $5 million charge consists of severance payments and related termination benefits, but the filing does not describe the terms offered to affected employees.
Sources
- LENZ Therapeutics, Inc., “Form 8-K Current Report,” U.S. Securities and Exchange Commission, October 28, 2026. https://www.sec.gov/Archives/edgar/data/1815776/000181577626000056/lenz-20261028.htm
- LENZ Therapeutics, “LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession,” October 28, 2026. https://www.sec.gov/Archives/edgar/data/1815776/000181577626000056/a991q326pressrelease.htm
Featured photo: Aerial view of the San Diego County coast around southern Encinitas and Solana Beach, California, Jan. 7, 2026. Representative image; not LENZ Therapeutics' offices. Photo: Joe Mabel, via Wikimedia Commons (CC BY-SA 4.0). Cropped from the original.
